Increased constitutive αSMA and Smad2/3 expression in idiopathic pulmonary fibrosis myofibroblasts is KCa3.1-dependent

Respiratory Research

Volumn 15, Issue 1, 2014, Pages

  Roach, Katy M ^a   Wulff, Heike ^b   Feghali Bostwick, Carol ^c   Amrani, Yassine ^a   Bradding, Peter ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Differentiation; Fibrosis; Idiopathic pulmonary fibrosis (IPF); Ion channel; KCa3.1; Lung; Myofibroblast; Smad 2; Smad 3

Indexed keywords

1 [(2 CHLOROPHENYL)DIPHENYLMETHYL] 1H PYRAZOLE; ALPHA SMOOTH MUSCLE ACTIN; CALCIUM ACTIVATED POTASSIUM CHANNEL; CALCIUM ION; POTASSIUM CHANNEL KCA3.1; SENICAPOC; SMAD2 PROTEIN; SMAD3 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL DEDIFFERENTIATION; CELL DIFFERENTIATION; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; EXTRACELLULAR CALCIUM; FIBROSING ALVEOLITIS; GENE EXPRESSION; HUMAN; HUMAN CELL; MYOFIBROBLAST; PROTEIN EXPRESSION; STRESS FIBER;

EID: 84928678504     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/s12931-014-0155-5     Document Type: Article

References (46)

1. Katzenstein AL, Myers JL: Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med. 1998, 157 (4 Pt 1): 1301-1315. 10.1164/ajrccm.157.4.9707039.
2. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G: Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006, 174 (7): 810-816. 10.1164/rccm.200602-163OC.
3. Flaherty KR, King TE, Raghu G, Lynch JP, Colby TV, Travis WD, Gross BH, Kazerooni EA, Toews GB, Long Q, Murray S, Lama VN, Gay SE, Martinez FJ: Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?. Am J Respir Crit Care Med. 2004, 170 (8): 904-910. 10.1164/rccm.200402-147OC.
4. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE, Kondoh Y, Myers J, Muller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, et al: An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management. Am J Respir Crit Care Med. 2011, 183 (6): 788-824. 10.1164/rccm.2009-040GL.
5. Schwartz DA, Helmers RA, Galvin JR, Van Fossen DS, Frees KL, Dayton CS, Burmeister LF, Hunninghake GW: Determinants of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1994, 149 (2 Pt 1): 450-454. 10.1164/ajrccm.149.2.8306044.
6. Gribbin J, Hubbard RB, Le Jeune I, Smith CJ, West J, Tata LJ: Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax. 2006, 61 (11): 980-985. 10.1136/thx.2006.062836.
7. Selman M, King TE, Pardo A: Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 2001, 134 (2): 136-151. 10.7326/0003-4819-134-2-200101160-00015.
8. Tomasek J, Gabbiani G, Hinz B, Chaponnier C, Brown R: Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol. 2002, 3 (5): 349-363. 10.1038/nrm809.
9. Sanders YY, Kumbla P, Hagood JS: Enhanced myofibroblastic differentiation and survival in Thy-1(-) lung fibroblasts. Am J Respir Cell Mol Biol. 2007, 36 (2): 226-235. 10.1165/rcmb.2006-0178OC.
10. Hinz B: Formation and function of the myofibroblast during tissue repair. J Invest Dermatol. 2007, 127 (3): 526-537. 10.1038/sj.jid.5700613.
11. Desmouliere A, Geinoz A, Gabbiani F, Gabbiani G: Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol. 1993, 122 (1): 103-111. 10.1083/jcb.122.1.103.
12. Skalli O, Schurch W, Seemayer T, Lagace R, Montandon D, Pittet B, Gabbiani G: Myofibroblasts from diverse pathologic settings are heterogeneous in their content of actin isoforms and intermediate filament proteins. Lab Invest. 1989, 60 (2): 275-285.
13. Thannickal VJ, Horowitz JC: Evolving concepts of apoptosis in idiopathic pulmonary fibrosis. Proc Am Thorac Soc. 2006, 3: 350-356. 10.1513/pats.200601-001TK.
14. Kuhn C, McDonald JA: The roles of the myofibroblast in idiopathic pulmonary fibrosis. Ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis. Am J Pathol. 1991, 138 (5): 1257-1265.
15. McAnulty RJ: Fibroblasts and myofibroblasts: their source, function and role in disease. Int J Biochem Cell Biol. 2007, 39 (4): 666-671. 10.1016/j.biocel.2006.11.005.
16. Grinnell F: Fibroblasts, myofibroblasts, and wound contraction. J Cell Biol. 1994, 124 (4): 401-404. 10.1083/jcb.124.4.401.
17. Ellabban NG, Lee KW: Myofibroblasts in Central Giant-Cell Granuloma of the Jaws - an Ultrastructural-Study. Histopathology. 1983, 7 (6): 907-918. 10.1111/j.1365-2559.1983.tb02305.x.
18. Hu B, Wu Z, Phan SH: Smad3 mediates transforming growth factor-beta-induced alpha-smooth muscle actin expression. Am J Respir Cell Mol Biol. 2003, 29 (3): 397-404. 10.1165/rcmb.2003-0063OC.
19. Gu L, Zhu Y, Yang X, Guo Z, Xu W, Tian X: Effect of TGF-beta/Smad signaling pathway on lung myofibroblast differentiation. Acta Pharmacol Sin. 2007, 28 (3): 382-391. 10.1111/j.1745-7254.2007.00468.x.
20. Nakao A, Imamura T, Souchelnytskyi S, Kawabata M, Ishisaki A, Oeda E, Tamaki K, Hanai J, Heldin CH, Miyazono K, TenDijke P: TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO J. 1997, 16 (17): 5353-5362. 10.1093/emboj/16.17.5353.
21. Zhou X, Wu W, Hu H, Milosevic J, Konishi K, Kaminski N, Wenzel SE: Genomic Differences Distinguish the Myofibroblast Phenotype of Distal Lung from Airway Fibroblasts. Am J Respir Cell Mol Biol. 2011, 46 (6): 1256-1262. 10.1165/rcmb.2011-0065OC.
22. Ca3.1 as a Novel Target for Idiopathic Pulmonary Fibrosis. PLoS ONE. 2013, 8 (12): e85244-10.1371/journal.pone.0085244.
23. Ca3.1 mediates activation of fibroblasts in diabetic renal interstitial fibrosis. Nephrol Dial Transplant. 2014, 29 (2): 313-324. 10.1093/ndt/gft431.
24. Ca3.1 ameliorates renal fibrosis through the TGF-beta1/Smad pathway in diabetic mice. Diabetes. 2013, 62 (8): 2923-2934. 10.2337/db13-0135.
25. Ca3.1 potassium channels. Proc Natl Acad Sci U S A. 2009, 106 (34): 14518-14523. 10.1073/pnas.0903458106.
26. Ramos C, Montaño M, García-Alvarez J, Ruiz V, Uhal BD, Selman M, Pardo A: Fibroblasts from Idiopathic Pulmonary Fibrosis and Normal Lungs Differ in Growth Rate, Apoptosis, and Tissue Inhibitor of Metalloproteinases Expression. Am J Respir Cell Mol Biol. 2001, 24 (5): 591-598. 10.1165/ajrcmb.24.5.4333.
27. Keira SM, Ferreira LM, Gragnani A, Duarte IS: Experimental model for fibroblast culture. Acta Cir Bras. 2004, 19: 11-16.
28. Pilewski JM, Liu LX, Henry AC, Knauer AV, Feghali-Bostwick CA: Insulin-like growth factor binding proteins 3 and 5 are overexpressed in idiopathic pulmonary fibrosis and contribute to extracellular matrix deposition. Am J Pathol. 2005, 166 (2): 399-407. 10.1016/S0002-9440(10)62263-8.
29. Pechkovsky DV, Hackett TL, An SS, Shaheen F, Murray LA, Knight DA: Human Lung Parenchyma but Not Proximal Bronchi Produces Fibroblasts with Enhanced TGF-(beta) Signaling and (alpha)-SMA Expression. Am J Respir Cell Mol Biol. 2010, 43 (6): 641-651. 10.1165/rcmb.2009-0318OC.
30. Zhao J, Shi W, Wang Y, Chen H, Bringas PJ, Datto MB, Frederick JP, Wang X, Warburton D: Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol. 2002, 282 (3): 585-593.
31. Wulff H, Miller MJ, Hansel W, Grissmer S, Cahalan MD, Chandy KG: Design of a potent and selective inhibitor of the intermediate-conductance Ca2+-activated K+ channel, IKCa1: a potential immunosuppressant. Proc Natl Acad Sci U S A. 2000, 97 (14): 8151-8156. 10.1073/pnas.97.14.8151.
32. Stocker JW, De Franceschi L, McNaughton-Smith GA, Corrocher R, Beuzard Y, Brugnara C: ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice. Blood. 2003, 101 (6): 2412-2418. 10.1182/blood-2002-05-1433.
33. Ca3.1. J Immunol. 2008, 180 (12): 8040-8047. 10.4049/jimmunol.180.12.8040.
34. Ca3.1 K+ channels are required for human lung mast cell migration. Thorax. 2006, 61 (10): 880-885. 10.1136/thx.2006.060319.
35. Hu L, Pennington M, Jiang Q, Whartenby KA, Calabresi PA: Characterization of the functional properties of the voltage-gated potassium channel Kv1.3 in human CD4+ T lymphocytes. J Immunol. 2007, 179 (7): 4563-4570. 10.4049/jimmunol.179.7.4563.
36. Shepherd MC, Duffy SM, Harris T, Cruse G, Schuliga M, Brightling CE, Neylon CB, Bradding P, Stewart AG: K(Ca)3.1 Ca2+-Activated K+ channels regulate human airway smooth muscle proliferation. Am J Respir Cell Mol Biol. 2007, 37 (5): 525-531. 10.1165/rcmb.2006-0358OC.
37. Emblom-Callahan MC, Chhina MK, Shlobin OA, Ahmad S, Reese ES, Iyer EPR, Cox DN, Brenner R, Burton NA, Grant GM, Nathan SD: Genomic phenotype of non-cultured pulmonary fibroblasts in idiopathic pulmonary fibrosis. Genomics. 2010, 96 (3): 134-145. 10.1016/j.ygeno.2010.04.005.
38. Bocchino M, Agnese S, Fagone E, Svegliati S, Grieco D, Vancheri C, Gabrielli A, Sanduzzi A, Avvedimento EV: Reactive Oxygen Species Are Required for Maintenance and Differentiation of Primary Lung Fibroblasts in Idiopathic Pulmonary Fibrosis. Plos One. 2010, 5 (11): e14003-10.1371/journal.pone.0014003.
39. Coward WR, Watts K, Feghali-Bostwick CA, Knox A, Pang L: Defective histone acetylation is responsible for the diminished expression of cyclooxygenase 2 in idiopathic pulmonary fibrosis. Mol Cell Biol. 2009, 29 (15): 4325-4339. 10.1128/MCB.01776-08.
40. Ca3.1 Regulates Vascular Smooth Muscle Cell Proliferation via Controlling Calcium-dependent Signaling. J Biol Chem. 2013, 288 (22): 15843-15853. 10.1074/jbc.M112.427187.
41. Ca3.1 K+ channels are required for human fibrocyte migration. J Allergy Clin Immunol. 2011, 128 (6): 1303-1309. 10.1016/j.jaci.2011.07.047. e2
42. Ca3.1 ameliorates T cell-mediated colitis. Proc Natl Acad Sci U S A. 2010, 107 (4): 1541-1546. 10.1073/pnas.0910133107.
43. Nesti LJ, Caterson EJ, Li W, Chang R, McCann TD, Hoek JB, Tuan RS: TGF-?1 calcium signaling in osteoblasts. J Cell Biochem. 2007, 101 (2): 348-359. 10.1002/jcb.21180.
44. Wicks SJ, Lui S, Abdel-Wahab N, Mason RM, Chantry A: Inactivation of Smad-transforming growth factor beta signaling by Ca2+-calmodulin-dependent protein kinase II. Mol Cell Biol. 2000, 20 (21): 8103-8111. 10.1128/MCB.20.21.8103-8111.2000.
45. Wrighton KH, Lin X, Feng X: Phospho-control of TGF-beta superfamily signaling. Cell Res. 2009, 19 (1): 8-20. 10.1038/cr.2008.327.
46. Ataga KI, Smith WR, De Castro LM, Swerdlow P, Saunthararajah Y, Castro O, Vichinsky E, Kutlar A, Orringer EP, Rigdon GC, Stocker JW: Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood. 2008, 111 (8): 3991-3997. 10.1182/blood-2007-08-110098.